Answers are grounded in this paper and cite their sources.
A new antibody-drug conjugate (ADC) chemical drug-linker platform based on polysarcosine enables increased drug-loading, improved pharmacokinetics and exquisite in vivo potency.
No takes yet. Share an insight, caveat, or question.
Viricel et al. (2019) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: